TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31950229

Group type: EXPERIMENTAL
Intervention: Insulin degludec 200 U/ml (degludec U200)
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Insulin glargine 300 U/ml (glargine U300)
Number of subjects: 1609
Study: 30497483

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy (10 sessions, twice a week for 5 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (conventional physical therapy and medication treatment)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 108
Study: 28026713

Group type: EXPERIMENTAL
Intervention: Modified intervention (ModTx)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Standard intervention (StnTx)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 78
Study: 25155416

Group type: EXPERIMENTAL
Intervention: Acid infusion into the distal esophagus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control infusion
Number of subjects: 0
Study: 22921577

Group type: EXPERIMENTAL
Intervention: Immediate referral for colposcopy
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Not in paid employment
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Increasing age and level of post-school education/training
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Women with children
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Not worried about having cervical cancer
Number of subjects: 2213

Group type: EXPERIMENTAL
Intervention: Anxiety and depression
Number of subjects: 2213
Study: 20377145

Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine (0.4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine
Number of subjects: 16
Study: 18296328

Group type: EXPERIMENTAL
Intervention: 50mg L-theanine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 15642700

Group type: EXPERIMENTAL
Intervention: Nebivolol (titrated from 1.25 mg once daily to 10 mg once daily, mean maintenance dose 7.7 mg)
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Placebo (mean maintenance dose 8.5 mg)
Number of subjects: 2128

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study: 12784841

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (mean blood alcohol concentration of .10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 40
Study: 11111630

Group type: EXPERIMENTAL
Intervention: Ankle strengthening and walking program (3-month supervised)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study: 9288412

Group type: EXPERIMENTAL
Intervention: 3 mg of haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.7 degree C‐increase in body core temperature due to 3‐h exposure to an ambient temperature of 52 degrees C
Number of subjects: 40
Study: 8327802

Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B
Number of subjects: 0
Study: 3525768

Group type: EXPERIMENTAL
Intervention: VMCP-VBAP without levamisole
Number of subjects: 440
Study: 29170792

Group type: EXPERIMENTAL
Intervention: 5% prilocaine/lidocaine (EMLA) cream
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin suppository
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (simple lubrication)
Number of subjects: 120
Study: 27335234

Group type: EXPERIMENTAL
Intervention: Laparoscopic simple enucleation (Group 1)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Laparoscopic enucleation-separation (Group 2)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 40
Study: 25680360

Group type: EXPERIMENTAL
Intervention: Psychotherapy users
Number of subjects: 482

Group type: COMPARATOR
Intervention: Medication only users
Number of subjects: 482

Group type: COMPARATOR
Intervention: Participants not utilizing medications or psychotherapy
Number of subjects: 482
Study: 23690342

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker treatment
Number of subjects: 1345
Study: 20427734

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (45 mg zinc/d as gluconate for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18987396

Group type: EXPERIMENTAL
Intervention: Topical hemostasis patch (SafeSeal Patch, Possis Medical Inc.) with manual pressure
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional manual pressure alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study: 16635793

Group type: EXPERIMENTAL
Intervention: Thymoglobulin (THY) 4.5 to 6.0 mg/kg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Targeted busulfan/cyclophosphamide (BUCY) without THY
Number of subjects: 56
Study: 12825855

Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg as a monthly intramuscular injection followed by subsequent endocrine therapy
Number of subjects: 423

Group type: COMPARATOR
Intervention: Subsequent endocrine therapy after no clinical benefit from fulvestrant
Number of subjects: 423
Study: 11023930

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 5 mg of P5 variant
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of 2.5 mg of P10 variant
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: P5, P10, P20 variants
Number of subjects: 29

Group type: COMPARATOR
Intervention: SakSTAR
Number of subjects: 29
Study: 8828024

Group type: EXPERIMENTAL
Intervention: Ebastine 10mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Terfenadine 60mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31204332

Group type: EXPERIMENTAL
Intervention: Charcoal infused bristle toothbrushes (T1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nylon bristle toothbrushes (T2)
Number of subjects: 25
Study: 29939261

Group type: EXPERIMENTAL
Intervention: Fresh amaranth forage (FAF)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ensiled amaranth without additive (EA)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EA + 5% of molasses (EAM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EA inoculated with LAB (EAB)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: EA inoculated with LAB + 5% of molasses (EABM)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 24‐h wilted EA (WEA)
Number of subjects: 6
Study: 27052934

Group type: EXPERIMENTAL
Intervention: NAVEOS navigation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Freehand positioning
Number of subjects: 78
Study: 23575879

Group type: EXPERIMENTAL
Intervention: Oral omega-3 fatty acids supplements for 12 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 22303592

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg twice daily)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (lactose pill twice daily)
Number of subjects: 8
Study: 18301124

Group type: EXPERIMENTAL
Intervention: quetiapine XR (once-daily equivalent dose)
Number of subjects: 497

Group type: COMPARATOR
Intervention: quetiapine IR (twice-daily)
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: quetiapine XR
Number of subjects: 497

Group type: COMPARATOR
Intervention: quetiapine IR
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: quetiapine XR and IR
Number of subjects: 497
Study: 17142407

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty
Number of subjects: 81

Group type: COMPARATOR
Intervention: Hemiarthroplasty
Number of subjects: 81
Study: 14503897

Group type: EXPERIMENTAL
Intervention: NRT plus telephone counselling (5 sessions)
Number of subjects: 854

Group type: COMPARATOR
Intervention: NRT alone
Number of subjects: 854
Study: 10699894

Group type: EXPERIMENTAL
Intervention: Chemotherapy based on the combination of cisplatin and etoposide
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chemotherapy and PC resection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pathology of the resected specimen
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Extent of disease (mediastinal only vs. visceral metastases)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: PC tumor markers
Number of subjects: 75
Study: 9068554

Group type: EXPERIMENTAL
Intervention: Gastrointestinal lavage solution (3 L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fasting alone (control group)
Number of subjects: 60
Study: 8403120

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia/analgesia
Number of subjects: 55

Group type: COMPARATOR
Intervention: Parenteral analgesia with morphine
Number of subjects: 55
Study: 2944913

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31931550

Group type: EXPERIMENTAL
Intervention: Chemoprophylaxis with 2.5 mg fondaparinux for 5 days postoperatively
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 133
Study: 29575241

Group type: EXPERIMENTAL
Intervention: Supported self‐management delivered by diabetes specialist nurses plus treatment as usual
Number of subjects: 82

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Supported self‐management
Number of subjects: 82
Study: 27593728

Group type: EXPERIMENTAL
Intervention: nVNS
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 150
Study: 25149199

Group type: EXPERIMENTAL
Intervention: Self-reported appetite scores measured by Visual Analogue Scales (VAS)
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: Without hunger as a factor
Number of subjects: 549
Study: 22234979

Group type: EXPERIMENTAL
Intervention: Higher levels of anxiety at baseline (OR 1.11; 95% CI 1.03 to 1.19, p=0.006) among people free of FGID at baseline.
Number of subjects: 1775

Group type: COMPARATOR
Intervention: FGID at baseline (no elevated anxiety and depression)
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Higher levels of anxiety and depression at baseline in IBS
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Depression at baseline in FD
Number of subjects: 1775
Study: 21189774

Group type: EXPERIMENTAL
Intervention: Oral midazolam (0.5 mg/kg) and submucosal fentanyl (3 microg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg) and submucosal placebo
Number of subjects: 23
Study: 18721122

Group type: EXPERIMENTAL
Intervention: Electrical stimulation combined with passive stretching (30 min of electrical stimulation of the quadriceps 3 times per week and passive stretching of the hamstrings 5 times per week)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive stretching of the hamstrings (5 times per week)
Number of subjects: 11
Study: 16397516

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (ARB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan, Valsartan, Irbesartan (other ARBs)
Number of subjects: 0
Study: 12707646

Group type: EXPERIMENTAL
Intervention: Active antigenic suspension
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 11069371

Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 104
Study: 8823335

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1‐hour intravenous infusion every 3 weeks
Number of subjects: 295

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus pamidronate
Number of subjects: 295
Study: 1418071

Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/d)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Cimetidine (800 mg/d)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Pirenzepine (75 mg/d)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 3965269

Group type: EXPERIMENTAL
Intervention: Domperidone (acute administration)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Domperidone (chronic administration, 35‐51 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 30021756

Group type: EXPERIMENTAL
Intervention: Natural S-equol supplement (10 mg a day, orally, twice daily for three menstrual cycles)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (orally, twice daily for three menstrual cycles)
Number of subjects: 124
Study: 26525214

Group type: EXPERIMENTAL
Intervention: Brachytherapy (Pd-103)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Brachytherapy (Pd-103) + supplemental external beam radiotherapy (EBRT)
Number of subjects: 630
Study: 25633713

Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B + GM-CSF
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-dose CpG-B
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 28
Study: 22985432

Group type: EXPERIMENTAL
Intervention: dexpramipexole 300 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: dexpramipexole 50 mg/day
Number of subjects: 0
Study: 20873594

Group type: EXPERIMENTAL
Intervention: Alarelin
Number of subjects: 122

Group type: COMPARATOR
Intervention: Triptorelin
Number of subjects: 122
Study: 18239661

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (MPH) 0.5 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16357400

Group type: EXPERIMENTAL
Intervention: Group 2 (fixed-duration injection protocol, 38 sec duration)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Group 1 (fixed-rate injection protocol, 3 or 4 mL/sec)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Group 3 (fixed-duration injection protocol, 47 sec duration)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 318
Study: 15004969

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Culture tests
Number of subjects: 134

Group type: COMPARATOR
Intervention: Luminescence microscopy
Number of subjects: 134
Study: 10881893

Group type: EXPERIMENTAL
Intervention: Routine stent implantation
Number of subjects: 479

Group type: COMPARATOR
Intervention: Balloon angioplasty with provisional stenting
Number of subjects: 479
Study: 9190140

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg/day
Number of subjects: 40
Study: 1301244

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 3009368

Group type: EXPERIMENTAL
Intervention: 6000 cGy irradiation
Number of subjects: 376

Group type: COMPARATOR
Intervention: 5000 cGy irradiation
Number of subjects: 376

Group type: COMPARATOR
Intervention: 4000 cGy irradiation (split course)
Number of subjects: 376

Group type: COMPARATOR
Intervention: 4000 cGy irradiation (continuous course)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 5000-6000 cGy irradiation with tumor control
Number of subjects: 376

Group type: COMPARATOR
Intervention: 5000-6000 cGy irradiation with intrathoracic failure
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 4000 cGy (split course) with tumor control
Number of subjects: 376

Group type: COMPARATOR
Intervention: 4000 cGy (split course) without tumor control
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 4000 cGy (continuous course) with tumor control
Number of subjects: 376

Group type: COMPARATOR
Intervention: 4000 cGy (continuous course) without tumor control
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Higher doses of irradiation
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Local tumor control at 12 months in advanced tumors (T4 or N3)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Thoracic failures in advanced tumors (T4 or N3)
Number of subjects: 376
Study: 31439367

Group type: EXPERIMENTAL
Intervention: Uncemented press-fit Regenerex® Porous Titanium Construct tibial tray and matching cemented patella and femoral components (hybrid implant)
Number of subjects: 80
Study: 28477718

Group type: EXPERIMENTAL
Intervention: Interventionists with <50 previous procedures
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: More experienced interventionists
Number of subjects: 313

Group type: COMPARATOR
Intervention: Strict selection of patients
Number of subjects: 313
Study: 26084556

Group type: EXPERIMENTAL
Intervention: Single-dose 400 mg albendazole
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1010
Study: 23908568

Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ranibizumab (1 mg)
Number of subjects: 16
Study: 21859920

Group type: EXPERIMENTAL
Intervention: Walking school bus program
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 19190051

Group type: EXPERIMENTAL
Intervention: Cementless Oxford unicompartmental knee replacement
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cemented Oxford unicompartmental knee replacement
Number of subjects: 62
Study: 17116941

Group type: COMPARATOR
Intervention: FEC (fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: FEC-D (three cycles of FEC followed by three cycles of docetaxel)
Number of subjects: 1999

Group type: COMPARATOR
Intervention: FEC
Number of subjects: 1999

Group type: EXPERIMENTAL
Intervention: FEC-D
Number of subjects: 1999
Study: 15489850

Group type: EXPERIMENTAL
Intervention: Transthoracic and transesophageal echocardiography
Number of subjects: 0
Study: 11351141

Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitors (ChE‐Is) including donepezil
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 423

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 423
Study: 9542575

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 396

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 396
Study: 8195995

Group type: EXPERIMENTAL
Intervention: Zinc phosphate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite resin‐glass ionomer hybrid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite resin‐glass ionomer hybrid with a dentinal bonding agent
Number of subjects: 0
Study: 3370922

Group type: EXPERIMENTAL
Intervention: 750 mg of alpha‐methyldopa
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 500 mg of alpha‐methyldopa
Number of subjects: 13
Study: 29580264

Group type: EXPERIMENTAL
Intervention: Cognitive training and physical exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive control and physical exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive training and physical exercise control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive control and physical exercise control
Number of subjects: 0
Study: 27505322

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (sham RIPC)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: RIPC
Number of subjects: 72
Study: 25700856

Group type: EXPERIMENTAL
Intervention: Internet-delivered applied relaxation
Number of subjects: 0
Study: 23981878

Group type: EXPERIMENTAL
Intervention: Budget for purchasing WASH-related items
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Additional funding for hiring a WASH attendant and making repairs to WASH infrastructure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Guides for student and community monitoring of conditions
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study: 21911944

Group type: EXPERIMENTAL
Intervention: Oil pulling with sesame oil
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chlorhexidine mouthwash
Number of subjects: 20
Study: 18989992

Group type: EXPERIMENTAL
Intervention: Nebicapone 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17015525

Group type: EXPERIMENTAL
Intervention: Nurse ratings
Number of subjects: 36

Group type: COMPARATOR
Intervention: Attending physician ratings
Number of subjects: 36
Study: 14530474

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study: 10952746

Group type: EXPERIMENTAL
Intervention: Radon and carbon dioxide baths (1.3 kBq/l, 1.6 g carbon dioxide/l on average)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham control (artificial carbon dioxide baths)
Number of subjects: 60
Study: 8828098

Group type: EXPERIMENTAL
Intervention: Endotoxin administration (Escherichia coli, Lot EC‐5, 4 ng/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antiendotoxin molecules
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mediator receptor antagonist
Number of subjects: 60

Group type: COMPARATOR
Intervention: Antimediator therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anti-inflammatory agents
Number of subjects: 60
Study: 1580285

Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Captopril (50-100 mg/day)
Number of subjects: 54
Study: 6342352

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg intravenously followed by 200 mg daily orally for 3 months)
Number of subjects: 1395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395